Gary Cartwright PhD

🚀 Don’t Miss Our Free Webinar: "Mastering Your Training Approaches in Pharma Safety" 🚀 Join our CEO, Dr Graeme Ladds, this week on 5th September for essential insights to enhance your safety training programs and help you stay ahead in the rapidly changing pharmaceutical industry. 📅 Date: 5th September 2024 ⏰ Times: 11:00 AM, 3:00 PM, 7:00 PM BST 📍 Location: Online Webinar (FREE) 🗣 Speaker: Dr. Graeme Ladds, CEO Why Attend? • Boost Your Training Programs: Learn to develop impactful safety training tailored to your organisation’s needs. • Stay Compliant: Gain a clear understanding of the latest regulatory requirements for safety training. • Innovate Your Approach: Discover new techniques that will transform how you train your teams. • Measure Success: Learn how to assess and improve the effectiveness of your training initiatives. • Real-World Insights: Explore case studies showcasing best practices in pharma safety training. Who Should Attend? • Training Managers and Coordinators in Pharma • Safety Officers and Professionals in the Pharmaceutical Industry • HR Professionals Specialising in Pharma and Healthcare • Quality Assurance and Compliance Personnel • Clinical Research Organisations (CROs) Staff Don’t miss this opportunity to enhance your training strategies and ensure your team is equipped for the challenges of pharmaceutical safety. 🔗 https://lnkd.in/eUffTJph Seats are filling up fast — secure your spot today!

5

In our latest article with PharmaTech Outlook, Dr Gary Watts, Senior Manager & Head of Formulation, discusses the important role that integrated development strategies play in helping to reduce the potential of formulation failure.   Gary highlights the criticality of a tailored formulation strategy, focusing on overcoming solubility, bioavailability, and controlled release challenges for complex biologics and bioconjugates. These insights demonstrate Abzena’s commitment to delivering optimized solutions that address the complex demands of modern biopharmaceutical drug development.   Read the full article here: https://lnkd.in/ecgm54xn   #FormulationDevelopment #Pharmaceuticals #DrugDevelopment #CRO #CDMO

41

What are the challenges to making the generics pharmaceutical sector more sustainable – and how can we overcome them?   Read more below, with insights from BGMA Sustainability Lead Michael Clarke   #Pharma #Sustainability

18

Interesting inphographic highlighting the technologies used by 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗗𝗠𝗢𝘀 who develop and manufacture 𝗙𝗶𝗻𝗶𝘀𝗵𝗲𝗱 𝗗𝗼𝘀𝗮𝗴𝗲 𝗙𝗼𝗿𝗺𝘀 of small molecules. 𝗧𝗢𝗣 𝟯! 🥇 Tablets (218 companies) 🥈 Capsules (192 companies) 🥉 Liquids (163 companies) 𝗞𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: 🧪 Increasing availability of CDMOs offering sterile glass vials over glass ampoules. 💉 Growing trend of CDMOs providing pre-filled syringes. 💊 Rise in CDMOs offering high-potency solids for Oral Solid Dosage forms. 🗜 Some CDMOs offer less common technologies such as blow fill seal amps, sterile bags, and cartridges. Full article by PharmaSource in comments... #CDMO #SmallMolecules #Pharma

28

2 Comments

How do you maximise the performance of your chemical process whilst meeting your budget and quality requirements? And, ultimately, how do you make sure you meet your clinical milestones? At CatSci Ltd, we have the answers. We've created a FREE interactive guide that outlines the steps required to advance your molecule to the clinic. Access our FREE guide here: https://lnkd.in/etpC9Tdg #ExcellenceInMedicinesDevelopment #DrugDevelopment #MedicinesDevelopment #SmallMolecules #HPAPIs #solidstate #crystallisation

3

As we reflect on the significant strides we made last year in reducing our greenhouse gas emissions and enhancing our sustainability practices, AlmaCrawler remains dedicated to building on these achievements in the years ahead. Our recent successes have laid a strong foundation, and we are committed to ensuring that our sustainability journey continues in a positive and impactful direction. While our accomplishments are a source of pride, we recognize that the path to sustainability is an ongoing one. We are focused on consolidating the gains we made in reducing energy intensity, greenhouse gas emissions, and overall energy consumption. At the same time, we aim to explore new opportunities for improvement, driven by our commitment to environmental stewardship and operational excellence. In the coming year, we plan to closely monitor our energy usage and emissions, seeking further efficiencies where possible. We are committed to evaluating and refining our processes, with the goal of enhancing our performance and reducing our environmental impact even further. This will involve ongoing collaboration across all levels of our organization, as we continue to engage our employees in our sustainability initiatives. We remain cautiously optimistic about our ability to meet future challenges and are committed to adapting our strategies as needed to achieve our long-term ESG goals. At AlmaCrawler, we look forward to continuing our work towards a more sustainable future. Together, we can build on our successes and contribute to a better world for generations to come. #almac #almacitalia #almacrawler #esg

24

Highlights from Day 1 of the Annual Punch and Dies Workshop Today marked the beginning of the Annual Punch and Dies Workshop 2024, bringing together industry professionals to exchange knowledge, explore new technologies, and strengthen collaborations within the pharmaceutical manufacturing sector. The day commenced with a compelling address from our director, setting a clear vision for the future of the industry. The focus was on revitalizing the pharmaceutical sector in Indonesia through sustainability and technological advancement. Emphasizing the importance of remaining competitive on a global scale, the address encouraged continuous innovation and adaptation. A significant moment was the introduction of Medial+, a brand that symbolizes the company’s ongoing commitment to excellence and precision in all aspects of its operations. The address also underscored the value of employees, recognizing their dedication and skills, highlighting that employee growth remains a core value of the company. The company emphasized its core value of providing opportunities for employee growth, ensuring that the team is well-prepared to lead the industry forward. One of the key moments of the day was the live demonstration of precision tableting techniques. Attendees had the opportunity to see advanced technology in action and consider its potential impact on their operations. This hands-on session offered valuable insights into the practical application of new tools and methods. Additionally, the discussion and demonstration of USP 1062, a new standard closely tied to emerging technologies, provided a detailed view of how these advancements are influencing the future of pharmaceutical manufacturing, with a particular focus on precision and efficiency. As Day 1 draws to a close, the anticipation for the insights and opportunities that tomorrow will bring continues to grow. The foundation has been laid for a successful workshop, reinforcing the importance of sustainability, technological progress, and the empowerment of employees in driving the industry forward. As we move forward, how will these new technologies shape your operations? Consider the potential impact as we explore the opportunities on Day 2! #APDW2024 #PunchAndDies #SustainabilityInPharma #PharmaTech #EmployeeEmpowerment #PharmaManufacturing #PrecisionEngineering #Day1Recap #PharmaWorkshop #FutureOfPharma #Medialplus #Plusgroup

17

📈 Quarterly Report LTR Pharma has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024. Key highlights from this period include: ✅ Pivotal clinical study of SPONTAN® fully recruited and completed dosing of all participants. ✅ SPONTAN achieved key manufacturing validation and first commercial batch production. ✅ SPONTAN is designed to be a world-first, fast-acting, on-demand Nasal Spray treatment for Erectile Dysfunction (ED). . LTR Pharma Chairman, Lee Rodne, said: "We are pleased to share that LTR Pharma has made significant strides towards bringing SPONTAN to market this quarter. We completed the dosing phase of the pivotal study and met critical FDA requirements for manufacturing validation. We remain on track with a strong cash position to achieve our milestones and revolutionise the global erectile dysfunction treatment landscape.” Read today’s ASX release here 👉 https://lnkd.in/gRbh9zNn $LTP #LTRPharma #ASX #menshealth #innovation #pharma #biotech #erectiledysfunction 

10

1 Comment

Meet Jane Provis-Evans: Head of GMP Analysis  In this article, we discuss her career journey in quality control, her dedication to ensuring better patient outcomes, and her vision for the future of GMP at Nanopharm. Read the full article below ⬇️ https://lnkd.in/e5zkzFvJ #Nanopharm #GMPAnalysis #QualityControl #PharmaceuticalInnovation 

43

This Nutraceutical Registration and Regulations in the UK (MHRA) are discussed in below points. Health Authority: The regulation and registration of nutraceuticals in the UK fall under the authority of the Medicines and Healthcare Products Regulatory Agency (MHRA). With their pivotal role, the MHRA is responsible for safeguarding the safety, quality, and effectiveness of nutraceutical products. Legal Representation: In the UK, manufacturers and importers of nutraceutical products must choose a legal representative based in the country. This representative plays a crucial role as a point of contact for regulatory authorities and takes responsibility for ensuring compliance with regulations. Product Classification: Nutraceutical products are classified into distinct categories depending on their purpose and composition. The primary categories consist of food supplements and traditional herbal medicinal products: Food Supplements are specifically formulated to complement regular dietary intake. They typically contain nutrients or other substances that offer nutritional or physiological effects. Common examples encompass vitamins, minerals, amino acids, and specific botanical extracts. Traditional Herbal Medicinal Products pertain to herbal-based remedies that make medicinal claims and are deemed suitable for addressing minor ailments. These products fall under the regulations imposed on medicinal effects due to their aforementioned therapeutic claims. For more information about the process and documents for registration email at [email protected] #Registration#UKNEUTRACEUTICAL#Regulatory#medicaldevices

16

🌟 Meet Our CSO, Professor Andrew Jamieson. 🌟 We are thrilled to announce that Keltic Pharma has been awarded a SMART Grant by Innovate UK to advance our innovative drug discovery platform, PEPSMOL©. This funding is a testament to our team’s dedication to pioneering new treatments for diseases that have been historically difficult to target. At Keltic Pharma, we're driven by scientific excellence and innovation and we’d like to introduce you to our Chief Scientific Officer, Professor Andrew Jamieson A founder of Keltic Pharma Therapeutics and a driving force behind our proprietary PEPSMOL© platform. Andrew brings a wealth of expertise in synthetic organic chemistry and peptide-based drug discovery, which is crucial to the ground-breaking work we're doing. Oh - and he also enjoys the odd glass of champagne when a celebration is in order 😀 With a distinguished career spanning over 20 years in both academia and industry, his work focuses on integrating the principles of synthetic chemistry and peptide engineering to create synthetic biologics, a new class of molecules that combine the best properties of small molecules and biologics like antibodies. Our initial focus with the PEPSMOL© platform is on inflammatory airway diseases, such as severe asthma that doesn’t respond to current treatments. The Keltic Pharma team have already validated the FFA4 receptor as a novel target in inflammatory lung disease, demonstrating the promise of our synthetic biologics approach in preclinical models. “With this SMART Grant, we can further validate the PEPSMOL© platform and explore new ways to treat severe asthma,” says Andrew. “We’re committed to leveraging our deep expertise in peptide chemistry and drug discovery to develop inhaled synthetic biologic drugs that offer new hope for patients.” Follow us for more updates as we continue to innovate and transform the future of drug discovery! 🌟 #Leadership #Biotech #Innovation #DrugDiscovery #SyntheticBiologics #GPCRs #Healthcare #SMARTGrant #InnovateUK #AsthmaTreatment #MedicalResearch #LifeSciences #KelticPharma #UniversityofGlasgow #AndrewJamieson

223

15 Comments

The Big Bad Bs in Biopharmaceutical Manufacturing. BPA and bDtBPP. You've probably heard of BPA when it comes to plastic utensils. BPA is an unwanted byproduct from polymer (plastic) production. BPA looks and acts estrogen and has been linked to a number of health issues, leading to it being banned in the production of drinking water bottles and baby bottles. Nowadays, most plastic utensils are now labeled as BPA-free. In the biopharmaceutical industry, the issue is with bDtBPP. bDtBPP is an unwanted byproduct from the manufacture of polymer bags used in single use bioreactors. You can learn more about the differences between traditional and single use bioreactors in our previous post: https://lnkd.in/eiz3cYwb bDtBPP has been shown to slow down cell growth - the exact opposite of what you want to happen in a bioreactor. Biopharm companies need to be extremely careful when deciding to switch from traditional bioreactors to single use bioreactors. Swipe through the guide below to learn more about the ways you can overcome the challenges to cell growth when using single use polymer bags in biopharmaceutical manufacturing. #biopharmaceuticalmanufacturing #singleusebioreactors #traditionalbioreactors #processengineering #quality

2

Highly potent active pharmaceutical ingredients, or HPAPIs, are a key capability for Lonza Small Molecules. They’re growing in importance in the pharmaceutical industry, with more than 1000 currently in development. But manufacturing them poses a range of technical and safety considerations. Lonza Small Molecules senior director Charlie Johnson has just had an article published in Speciality Chemicals magazine that explains the challenges involved in making HPAPIs, and how CDMOs like Lonza can help. Making HPAPIs requires a significant investment in containment equipment, and expert operators to run them. This is something Lonza has put a substantial focus on in recent years, leaving us well placed to assist customers with their HPAPI projects. If you’d like to know more about the challenges involved in making HPAPIs, you can read Charlie’s article in the magazine online. It’s on page 16. And do get in touch with us if you’d like to discover how Lonza Small Molecules can help make your HPAPI a reality. https://lnkd.in/ee_HXNUz #LonzaSM #HPAPI #HPAPITrends #ADC #SpecialityChemicals #Outsourcing

142

3 Comments

Join our Group Director of Medicines Access & UK General Manager, Rebecca Bibby, as she contributes to the panel discussion 'Navigating Success: Insights from MSDUK's EMB and Corporate Partnership Journey' at the MSDUK Business Opportunity Day. Gain insights into GSK's partnership journey with BAP Pharma and discover the significance of nurturing a varied supplier pool and strategies for establishing prosperous partnerships with diversly owned suppliers. #supplierdiversity #MSDUK #diversebusiness #BusinessOpportunityDay #clinicaltrials #healthcare #medicine #biotechnology #pharmaceuticals #pharmaceuticalindustry

34

3 Comments

🚀 Ready to tackle the biggest regulatory challenges? Our free webinar is just around the corner! Join our CEO, Dr Graeme Ladds, next week for an essential session in our webinar series: "Biggest Regulatory Challenges and Opportunities to Address for your Company". Explore the critical regulatory issues impacting the pharmaceutical industry and discover effective strategies to navigate them, enhancing your compliance and gaining a strategic advantage. 📅 Date: 26th June 2024 ⏰ Times: 11:00 AM, 3:00 PM, 7:00 PM GMT 📍 Location: Online Webinar (Free) 🗣 Speaker: Dr Graeme Ladds, CEO Why Join? • Gain key insights into regulatory frameworks • Enhance compliance and risk management • Leverage opportunities to gain a competitive advantage Perfect for: • Senior Company Executives (CEO, CFO, Compliance, CSO, Chief Medical Officer) • Regulatory Affairs VP/Director/Managers and Compliance Officers • Quality Assurance Professionals, Procurement • Research and Development Personnel, Clinical Affairs • Legal Advisors 🔗 Register Now: https://lnkd.in/eqmSzTEP Don’t miss this chance to equip yourself with the knowledge to navigate regulatory landscapes effectively. Secure your spot today! #PharSafer #Webinar #Free #BusinessLeadership #ThoughtLeadership #Pharmacovigilance #RegulatoryCompliance #RiskManagement

11

With the focus so often being on getting the product certified by a Qualified Person (QP) under a Manufacturers/Importers Authorisation (MIA), what can often be overlooked is what is needed to actually get the product out of the warehouse and in to hands of the patient. Enter the Wholesale Distributors Authorisation (WDA) and the key person within that, the Responsible Person (RP). To read more on the steps involved in getting a WDA licence visit; https://lnkd.in/etBnC4Zp #miaspharma #licence #wda #RP #MIA #QP

14

Head of Quality Peter Rooney sat down with Peter Deegan last week to share his rich experience in pharmaceutical audits from a quality perspective - both in conducting and preparing to host. If you missed last weeks episode of our podcast My Auditing Journey you can catch it on the links below 👇

10

Despite there being so many great quality leaders in biotech... ..we're still seeing talented QA and QC professionals hesitant to step into leadership roles. Why is this?   - Lack of clarity on career prospects? - Very few role models or inspiring mentors? - Poor perceptions of quality as an industry? - Certain leaders making the job look unattractive? - Senior leadership not seeing the value in quality? This is leading to:   - Leaders focussed on tactical work instead of strategic - Under-resourced teams and high-workload - Stress and burn-out amongst QA leaders - Inability to progress career further *** To address this, in 2025, we’re launching a Mentor Scheme to help evolve our mission of supporting and developing the next generation of quality leaders. The initiative is designed to connect the best Quality leaders in Life Sciences with those eager to grow, learn, and take their careers to the next level. So... ➡️ If you are a quality professional and would like to be mentored by a leader with a proven track record of developing people's careers. OR ➡️ You are a leader who is passionate about inspiring and developing the next generation of quality leaders. Then this could be for you! We already have over 20 of the best leaders in the industry signed up as mentors, ready to help develop someone's career. 🚀 Click the link in the comments to sign up to the waiting list.⬇️

40

8 Comments

As #pharmaceutical companies look to reduce the time to market of their drugs while producing quality formulations, the benefits of outsourcing formulation development have become more apparent. Colin Lorimer, Associate Director of Formulation Development at Almac Pharma Services, discusses why companies should consider outsourcing this portion of the development process. #drugdevelopment #pharma #outsourcing #drugformulation Almac Group

1